Literature DB >> 23343467

Subtyping first-episode non-affective psychosis using four early-course features: potentially useful prognostic information at initial presentation.

Michael T Compton1, Mary E Kelley, Dawn F Ionescu.   

Abstract

AIM: Heterogeneity of symptoms, course and outcomes in primary psychotic disorders complicates prognosis, treatment and diverse aspects of research. This study aimed to identify interpretable subtypes of first-episode non-affective psychosis based on four early-course features (premorbid academic functioning, premorbid social functioning, duration of the prodrome and age at onset of psychosis).
METHODS: Data from 200 well-characterized patients hospitalized in public-sector inpatient units for first-episode non-affective psychosis were used in latent profile analyses. Derived subtypes were then compared along a number of clinical dimensions using analyses of variance.
RESULTS: Using four early-course features, three classes were derived. A good premorbid/short prodrome subtype was characterized by a lower severity of positive symptoms, better social/occupational/global functioning, and a shorter duration of untreated psychosis; a poor premorbid/early onset subtype demonstrated greater negative and preoccupation symptoms, as well as greater psychosocial problems; and a long prodrome/late onset subtype was characterized by greater dysphoric symptoms.
CONCLUSIONS: Findings indicate a need for further research with first-episode samples on the utility of subtyping based on early-course (premorbid, prodromal and onset-related) characteristics. Such efforts could enhance the parsing of heterogeneity, thereby advancing clinical practice and research.
© 2013 Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  age at onset; first-episode psychosis; premorbid functioning; prodrome; schizophrenia

Mesh:

Year:  2013        PMID: 23343467      PMCID: PMC3672389          DOI: 10.1111/eip.12026

Source DB:  PubMed          Journal:  Early Interv Psychiatry        ISSN: 1751-7885            Impact factor:   2.732


  61 in total

1.  Predictors of the discharge dosage of an atypical antipsychotic agent among hospitalized, treatment-naive, first-episode psychosis patients in naturalistic, public-sector settings.

Authors:  Michael T Compton; Mary E Kelley; Robert Brett Lloyd; Tamela McClam; Claire E Ramsay; Patrick J Haggard; Sara Augustin
Journal:  J Clin Psychopharmacol       Date:  2011-02       Impact factor: 3.153

2.  Mode of onset of psychosis and family involvement in help-seeking as determinants of duration of untreated psychosis.

Authors:  Michael T Compton; Victoria H Chien; Amy S Leiner; Sandra M Goulding; Paul S Weiss
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-07-05       Impact factor: 4.328

3.  Testing systems for assessment of negative symptoms in schizophrenia.

Authors:  W S Fenton; T H McGlashan
Journal:  Arch Gen Psychiatry       Date:  1992-03

4.  Patient-level predictors and clinical correlates of duration of untreated psychosis among hospitalized first-episode patients.

Authors:  Michael T Compton; Tynessa L Gordon; Sandra M Goulding; Michelle L Esterberg; Tandrea Carter; Amy S Leiner; Paul S Weiss; Benjamin G Druss; Elaine F Walker; Nadine J Kaslow
Journal:  J Clin Psychiatry       Date:  2011-02       Impact factor: 4.384

5.  Family-level predictors and correlates of the duration of untreated psychosis in African American first-episode patients.

Authors:  Michael T Compton; Sandra M Goulding; Tynessa L Gordon; Paul S Weiss; Nadine J Kaslow
Journal:  Schizophr Res       Date:  2009-10-14       Impact factor: 4.939

6.  Health services determinants of the duration of untreated psychosis among African-American first-episode patients.

Authors:  Michael T Compton; Claire E Ramsay; Ruth S Shim; Sandra M Goulding; Tynessa L Gordon; Paul S Weiss; Benjamin G Druss
Journal:  Psychiatr Serv       Date:  2009-11       Impact factor: 3.084

7.  Prevalence and correlates of school drop-out prior to initial treatment of nonaffective psychosis: further evidence suggesting a need for supported education.

Authors:  Sandra M Goulding; Victoria H Chien; Michael T Compton
Journal:  Schizophr Res       Date:  2009-09-24       Impact factor: 4.939

8.  Beyond symptom dimensions: schizophrenia risk factors for patient groups derived by latent class analysis.

Authors:  S J Leask; J K Vermunt; D J Done; T J Crow; M Blows; M P Boks
Journal:  Schizophr Res       Date:  2009-10-18       Impact factor: 4.939

9.  Association of pre-onset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients.

Authors:  Michael T Compton; Mary E Kelley; Claire E Ramsay; Makenya Pringle; Sandra M Goulding; Michelle L Esterberg; Tarianna Stewart; Elaine F Walker
Journal:  Am J Psychiatry       Date:  2009-10-01       Impact factor: 18.112

10.  Deconstructing Psychosis conference February 2006: the validity of schizophrenia and alternative approaches to the classification of psychosis.

Authors:  Judith Allardyce; Wolfgang Gaebel; Jurgen Zielasek; Jim van Os
Journal:  Schizophr Bull       Date:  2007-06-04       Impact factor: 9.306

View more
  3 in total

1.  Early onset first episode psychosis: dimensional structure of symptoms, clinical subtypes and related neurodevelopmental markers.

Authors:  Maria Giuseppina Petruzzelli; Lucia Margari; Andrea Bosco; Francesco Craig; Roberto Palumbi; Francesco Margari
Journal:  Eur Child Adolesc Psychiatry       Date:  2017-07-26       Impact factor: 4.785

Review 2.  A Synthetic Literature Review on the Management of Emerging Treatment Resistance in First Episode Psychosis: Can We Move towards Precision Intervention and Individualised Care?

Authors:  Siân Lowri Griffiths; Max Birchwood
Journal:  Medicina (Kaunas)       Date:  2020-11-24       Impact factor: 2.430

Review 3.  Systematic review of pathways to care in the U.S. for Black individuals with early psychosis.

Authors:  Oladunni Oluwoye; Beshaun Davis; Franchesca S Kuhney; Deidre M Anglin
Journal:  NPJ Schizophr       Date:  2021-12-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.